EVOKE 01
EVOKE-01: Phase III Trial of Sacituzumab Govitecan vs Docetaxel in Patients With Previously Treated Advanced NSCLC

Released: June 02, 2024

Expiration: June 01, 2025

Activity

Progress
1
Course Completed